Rhythm Pharmaceuticals, Inc. (RYTM) — Financial statements
Income statement, balance sheet, and cash flow for Rhythm Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 190↑45.8% | 130↑68.1% | 77↑227.6% | 24↑649.5% | 3 | |
| Cost of Revenue | 19↑45.8% | 13↑43.7% | 9↑336.1% | 2↑256.1% | 0.60 | |
| Gross Profit | 170↑45.8% | 117↑71.4% | 68↑216.8% | 22↑741.7% | 3 | |
| Operating Expenses | ||||||
| R&D Expenses | 167↓29.7% | 238↑76.3% | 135↑24.2% | 109↑4.3% | 104 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 195↑35.1% | 144↑22.8% | 118↑27.7% | 92↑34.4% | 68 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 362↓5.2% | 382↑51.4% | 252↑25.8% | 201↑16.2% | 173 | |
| Total Costs & Expenses | 382↓3.5% | 396↑51.1% | 262↑29.1% | 203↑17.1% | 173 | |
| Operating Results | ||||||
| Operating Income | -192↑27.7% | -266↓44.0% | -184↓2.9% | -179↓5.3% | -170 | |
| Depreciation & Amortization | 1↓14.4% | 2↓11.1% | 2↑5.1% | 2↑44.4% | 1 | |
| EBITDA | -174↑26.9% | -238↓41.3% | -168↑3.3% | -174↓154.5% | -68 | |
| EBIT | -175↑26.8% | -240↓40.8% | -170↑3.2% | -176↓152.7% | -70 | |
| Interest & Other Income | ||||||
| Net Interest Income | -5↑10.2% | -6↓11217.0% | 0.05↑104.5% | -1↓362.2% | 0.45 | |
| Interest Income | 15↑4.0% | 15↑5.5% | 14↑246.1% | 4↑801.3% | 0.45 | |
| Interest Expense | 21↓0.1% | 21↑48.3% | 14↑167.1% | 5 | 0.00 | |
| Non-Operating Income | -17↑35.9% | -26↓82.9% | -14↓336.4% | -3↑96.8% | -100 | |
| Other Income / Expenses | -4↓176.7% | 5↑2059.3% | 0.24↑112.4% | -2↓102.0% | 100 | |
| Income Before Tax | -196↑24.7% | -260↓41.4% | -184↓1.7% | -181↓160.2% | -70 | |
| Income Tax Expense | 0.50↑43.6% | 0.35↓38.7% | 0.56 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -197↑24.6% | -261↓41.1% | -185↓2.0% | -181↓160.2% | -70 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -197↑24.6% | -261↓41.1% | -185↓2.0% | -181↓160.2% | -70 | |
| Bottom-Line Net Income | -202↑23.7% | -265↓43.3% | -185↓2.0% | -181↓160.2% | -70 | |
| EPS (Basic) | -3.11↑28.3% | -4.34↓35.6% | -3.20↑8.8% | -3.51↓156.2% | -1.37 | |
| EPS (Diluted) | -3.11↑28.3% | -4.34↓35.6% | -3.20↑8.8% | -3.51↓156.2% | -1.37 | |
| Weighted Average Shares | 65↑6.5% | 61↑5.8% | 58↑10.7% | 52↑5.1% | 50 | |
| Weighted Average Diluted Shares | 65↑6.5% | 61↑5.8% | 58↑10.7% | 52↑5.1% | 50 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.